Stroke represents one of the main causes of adult disability and will be one of the main contributors to the burden of disease in 2030. However, the healthcare systems are not able to respond to the current demand let alone its future increase. There is a need to deploy new approaches that advance current rehabilitation methods and enhance their efficiency. One of the latest approaches used for the rehabilitation of a wide range of deficits of the nervous system is based on virtual reality (VR) applications, which combine training scenarios with dedicated interface devices such as the Rehabilitation Gaming System (RGS), a science-based ICT solution for neurorehabilitation combining brain theory, AI, cloud computing and virtual reality and targeting motor and cognitive recovery after stroke. RGS provides a continuum of evaluations and therapeutic solutions that accompany the patient from the clinic to the therapy centre. RGS has been clinically validated. However, in order to achieve significant benefits in the patients' QoL, it is essential that this technological solution becomes an at home solution providing training and 24/7 monitoring and care. For this reason, this project aims at investigating not only its clinical validity but also the RGS acceptability and adoption model. The findings derived from this study will contribute to establish a novel neurorehabilitation paradigm that can accelerate the recovery of hemiparetic stroke patients. Besides the clinical impact, such achievement could have relevant socioeconomic impact.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
University Miguel Hernandez - Specs Lab
Elche, Alicante, Spain
Barthel Index (BI) [min=0, max =100]. Higher scores indicate better functioning.
Changes from baseline to end of treatment (12 weeks)
Time frame: 12 weeks
Barthel Index (BI) [min=0, max =100]. Higher scores indicate better functioning.
Changes from baseline to follow up (6 months)
Time frame: 6 months
Barthel Index (BI) [min=0, max =100]. Higher scores indicate better functioning.
Changes from baseline to follow up (12 months)
Time frame: 12 months
Fugl-Meyer Upper Extremities (FM-UE) [min=0, max=66]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 weeks)
Time frame: 12 weeks
Fugl-Meyer Upper Extremities (FM-UE) [min=0, max=66]. Higher scores indicate better functioning.
Change in score from baseline to follow-up (6 months)
Time frame: 6 months
Fugl-Meyer Upper Extremities (FM-UE) [min=0, max=66]. Higher scores indicate better functioning.
Change in score from baseline to follow-up (12 months)
Time frame: 12 months
CAHAI [min=13, max=91]. Higher scores indicate better functioning.
Change in score from baseline to the end of treatment and follow-up
Time frame: 12 weeks
CAHAI [min=13, max=91]. Higher scores indicate better functioning.
Change in score from baseline to the end of treatment and follow-up
Time frame: 12 months
Hamilton Depression Scale [min=0, max=52]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow up
Time frame: 12 weeks
Hamilton Depression Scale [min=0, max=52]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow up
Time frame: 12 months
Fatigue Severity Scale (FSS) [min=9, max=63]. Higher scores indicate more fatigue.
Change in score from baseline to end of treatment and follow up.
Time frame: 12 weeks
Fatigue Severity Scale (FSS) [min=9, max=63]. Higher scores indicate more fatigue.
Change in score from baseline to end of treatment and follow up.
Time frame: 12 months
Visual Analogue Score (VAS) [min=0, max=10]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow up
Time frame: 12 weeks
Visual Analogue Score (VAS) [min=0, max=10]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow up
Time frame: 12 months
Modified Ashworth Scale (MAS) [min=0, max=4]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow-up
Time frame: 12 weeks
Modified Ashworth Scale (MAS) [min=0, max=4]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment and follow-up
Time frame: 12 months
Stroke Impact Scale (SIS) [min=0, max=42]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment and follow-up
Time frame: 12 weeks
Stroke Impact Scale (SIS) [min=0, max=42]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment and follow-up
Time frame: 12 months
Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment and follow up
Time frame: 12 weeks
Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment and follow up
Time frame: 12 months
Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Change in score from baseline to end of treatment and follow up
Time frame: 12 weeks
Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Change in score from baseline to end of treatment and follow up
Time frame: 12 months
Number of participants readmitted to the hospital after being discharged to at-home status.
Number of patients from baseline to 12 months post-baseline.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.